EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC0

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment

Nicholas Winters iD, Mireille E Schnitzer, Jonathon R Campbell, Susannah Ripley, Carla Winston, Rada Savic, Nafees Ahmad iD, Gregory Bisson, Keertan Dheda, Ali Esmail, Medea Gegia, Ignacio Monedero und 5 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0292106 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, 2023. Verfasst von Nicholas Winters und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: World Health Organization, Tuberculosis Epidemiologic Studies Consortium of CDC and by other CDC projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Studying treatment duration for rifampicin-resistant and multidrug-resistant tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We aim to present a hypothesis generating approach to identify factors associated with shorter duration of treatment. Study design and setting We conducted an individual patient data meta-analysis among MDR/RR-TB patients restricted to only those with successful treatment outcomes. Using multivariable linear regression, we estimated associations and their 95% confidence intervals (CI) between the outcome of individual deviation in treatment duration (in months) from the mean duration of their treatment site and patient characteristics, drug resistance, and treatments used.

Results

Overall, 6702 patients with successful treatment outcomes from 84 treatment sites were included. We found that factors commonly associated with poor treatment outcomes were also associated with longer treatment durations, relative to the site mean duration. Use of bedaquiline was associated with a 0.51 (95% CI: 0.15, 0.87) month decrease in duration of treatment, which was consistent across subgroups, while MDR/RR-TB with fluoroquinolone resistance was associated with 0.78 (95% CI: 0.36, 1.21) months increase.

Conclusion

We describe a method to assess associations between clinical factors and treatment duration in observational studies of MDR/RR-TB patients, that may help identify patients who can benefit from shorter treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantHumansAntitubercular AgentsDuration of TherapyFluoroquinolonesRifampinTreatment Outcome

Substanzen

Antitubercular AgentsFluoroquinolonesRifampin

Autor:innen und Institutionen

  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.
  • Faculty of Pharmacy, Université de Montréal, Montreal, Canada.
  • Department of Social and Preventive Medicine, Université de Montréal, Montreal, Canada.
  • Department of Medicine & Department of Global and Public Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.
  • McGill International TB Centre, Montreal Chest Institute, Research Institute of the McGill University Health Centre, Montreal, Canada.
  • Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, Canada.

ORCID-Profile: Nicholas Winters, Nafees Ahmad, Margareth Pretti Dalcolmo

Förderung

  • World Health Organization
  • Tuberculosis Epidemiologic Studies Consortium of CDC and by other CDC projects

Zitieren

APA

Winters, N., Schnitzer, M. E., Campbell, J. R., Ripley, S., Winston, C., Savic, R., Ahmad, N., Bisson, G., Dheda, K., Esmail, A., Gegia, M., Monedero, I., Dalcolmo, M. P., Rodrigues, D., Singla, R., Yim, J. J., & Menzies, D. (2023). Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment. PLOS ONE. https://doi.org/10.1371/journal.pone.0292106

Vancouver

Winters N, Schnitzer ME, Campbell JR, Ripley S, Winston C, Savic R, et al. Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment. PLOS ONE. 2023. doi:10.1371/journal.pone.0292106

BibTeX
@article{Winters2023,
  author = {Winters, Nicholas and Schnitzer, Mireille E and Campbell, Jonathon R and Ripley, Susannah and Winston, Carla and Savic, Rada and Ahmad, Nafees and Bisson, Gregory and Dheda, Keertan and Esmail, Ali and Gegia, Medea and Monedero, Ignacio and Dalcolmo, Margareth Pretti and Rodrigues, Denise and Singla, Rupak and Yim, Jae-Joon and Menzies, Dick},
  title = {Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0292106}
}
Kostenlos starten →